<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874092</url>
  </required_header>
  <id_info>
    <org_study_id>15-01003</org_study_id>
    <nct_id>NCT02874092</nct_id>
  </id_info>
  <brief_title>Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis</brief_title>
  <acronym>TIMERA</acronym>
  <official_title>Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study to assess the improvement in the Disease Activity Score for&#xD;
      28-joint counts (DAS28) with ticagrelor given at 90 mg twice daily in patients with RA who&#xD;
      have active disease despite MTX therapy (as defined by the inclusion/exclusion criteria).&#xD;
      There will also be a cross sectional analysis of baseline platelet activity in subjects with&#xD;
      rheumatoid arthritis and osteoarthritis. Subjects in the OA cohort will not receive any study&#xD;
      medication, and will only have one study visit.&#xD;
&#xD;
      Patients will receive 90 mg ticagrelor orally bid. The patients will receive drug for&#xD;
      30-days. Methotrexate dose will remain stable throughout the study duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two main goals of this study are to demonstrate the heightened cardiovascular risk in RA&#xD;
      by comparing platelet activity, inflammation and endothelial function in baseline rheumatoid&#xD;
      arthritis versus age- and sex-matched patients with osteoarthritis; and 2) to demonstrate the&#xD;
      effect of ticagrelor in rheumatoid arthritis by the pre- and post- measures of clinical RA&#xD;
      severity, platelet activity, inflammation and endothelial function in rheumatoid arthritis&#xD;
      before and after ticagrelor therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">June 19, 2019</completion_date>
  <primary_completion_date type="Actual">April 19, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score for 28-joint Counts (DAS28)</measure>
    <time_frame>30 Days</time_frame>
    <description>The DAS28 is a composite score derived from 4 of these measures. This '28' version is a simplification of the original DAS score, which requires 44 joints to be counted. Other versions of the DAS28 allow the CRP to be used instead of the ESR, or the omission of either. To calculate the DAS28 your rheumatologist or specialist nurse will:-&#xD;
count the number of swollen joints (out of the 28), count the number of tender joints (out of the 28), take blood to measure the erythrocyte sedimentation rate (ESR) or C reactive protein (CRP), ask you (the patient) to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).&#xD;
These results are then fed into a complex mathematical formula to produce the overall disease activity score. A DAS28 of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.&#xD;
The total scale range is from 2 to 10, with higher scores indicating more disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Disease Activity</measure>
    <time_frame>30 Days</time_frame>
    <description>The VAS is a psychometric response scale that ranges from &quot;no pain&quot; (0) to &quot;worst pain&quot; (100); patients mark a line on a continuum to indicate how they are feeling. Provides global assessment of RA severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brachial Artery Diameter</measure>
    <time_frame>Baseline, 30 Days</time_frame>
    <description>Endothelial function is characterized by flow-mediated vasodilation of the brachial artery, which is measured by comparing the brachial artery diameter at rest the diameter after increased forearm blood flow (reactive hyperemia). Brachial artery reactivity testing (BART) is a noninvasive technique for evaluating endothelial function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoarthritis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Diagnosis of osteoarthritis made by physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX therapy</intervention_name>
    <arm_group_label>Osteoarthritis</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        RA cohort&#xD;
&#xD;
          -  Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
&#xD;
          -  Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low&#xD;
             if the DAS28 is 3.2 or less) (Prevoo et al., 1995)&#xD;
&#xD;
        OA cohort&#xD;
&#xD;
          -  Diagnosis of osteoarthritis made by physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        RA cohort&#xD;
&#xD;
          -  History of sensitivity to study medications or any of their excipients&#xD;
&#xD;
          -  Previous intolerance to MTX&#xD;
&#xD;
          -  Current treatment with antiplatelet therapy&#xD;
&#xD;
          -  Absolute indication for anti-platelet therapy&#xD;
&#xD;
          -  Need for chronic oral anticoagulant therapy&#xD;
&#xD;
          -  Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy)&#xD;
&#xD;
          -  Renal failure (eGFR &lt;30 or requiring dialysis)&#xD;
&#xD;
          -  A known bleeding diathesis, hemostatic or coagulation disorder, or prior major&#xD;
             bleeding&#xD;
&#xD;
          -  Prior stroke&#xD;
&#xD;
          -  Active pathological bleeding&#xD;
&#xD;
          -  History of intracranial haemorrhage&#xD;
&#xD;
          -  Life expectancy &lt;12 months based on investigator's judgement&#xD;
&#xD;
          -  Patients considered to be at risk of bradycardic events (e.g., known sick sinus&#xD;
             syndrome or second or third degree atrioventricular [AV)] block) unless already&#xD;
             treated with a permanent pacemaker&#xD;
&#xD;
          -  Anemia (hematocrit &lt; 27%)&#xD;
&#xD;
          -  Platelet count &lt; 100,000/ml&#xD;
&#xD;
          -  Concomitant use of strong CYP 3A inhibitors or inducers&#xD;
&#xD;
          -  History of thrombocytopenia or neutropenia&#xD;
&#xD;
          -  Pregnant or nursing women, or females with a positive pregnancy test at screening&#xD;
&#xD;
          -  Females of child bearing potential not using acceptable method of birth control prior&#xD;
             to or during study&#xD;
&#xD;
          -  Concern for inability of the patient to comply with study procedures and/or follow up&#xD;
             (eg, alcohol or drug abuse)&#xD;
&#xD;
        OA cohort:&#xD;
&#xD;
          -  History of sensitivity to study medications or any of their excipients&#xD;
&#xD;
          -  Current treatment with antiplatelet therapy&#xD;
&#xD;
          -  Absolute indication for anti-platelet therapy&#xD;
&#xD;
          -  Need for chronic oral anticoagulant therapy&#xD;
&#xD;
          -  Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy)&#xD;
&#xD;
          -  Renal failure (eGFR &lt;30 or requiring dialysis)&#xD;
&#xD;
          -  A known bleeding diathesis, hemostatic or coagulation disorder, or prior major&#xD;
             bleeding&#xD;
&#xD;
          -  Prior stroke&#xD;
&#xD;
          -  Active pathological bleeding&#xD;
&#xD;
          -  History of intracranial haemorrhage&#xD;
&#xD;
          -  Life expectancy &lt;12 months based on investigator's judgement&#xD;
&#xD;
          -  Anemia (hematocrit &lt; 27%)&#xD;
&#xD;
          -  Platelet count &lt; 100,000/ml&#xD;
&#xD;
          -  History of thrombocytopenia or neutropenia&#xD;
&#xD;
          -  Pregnant or nursing women, or females with a positive pregnancy test at screening&#xD;
&#xD;
          -  Females of child bearing potential not using acceptable method of birth control prior&#xD;
             to or during study&#xD;
&#xD;
          -  Concern for inability of the patient to comply with study procedures and/or follow up&#xD;
             (eg, alcohol or drug abuse)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <results_first_submitted>May 27, 2021</results_first_submitted>
  <results_first_submitted_qc>September 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methotrexate (MTX)</keyword>
  <keyword>Ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02874092/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis</title>
          <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
Ticagrelor&#xD;
MTX therapy</description>
        </group>
        <group group_id="P2">
          <title>Osteoarthritis</title>
          <description>-Diagnosis of osteoarthritis made by physician.&#xD;
MTX therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis</title>
          <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
Ticagrelor&#xD;
MTX therapy</description>
        </group>
        <group group_id="B2">
          <title>Osteoarthritis</title>
          <description>-Diagnosis of osteoarthritis made by physician.&#xD;
MTX therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Baseline age was only collected for the 7 RA participants</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="16"/>
                    <measurement group_id="B3" value="48" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="2"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Activity Score for 28-joint Counts (DAS28)</title>
        <description>The DAS28 is a composite score derived from 4 of these measures. This '28' version is a simplification of the original DAS score, which requires 44 joints to be counted. Other versions of the DAS28 allow the CRP to be used instead of the ESR, or the omission of either. To calculate the DAS28 your rheumatologist or specialist nurse will:-&#xD;
count the number of swollen joints (out of the 28), count the number of tender joints (out of the 28), take blood to measure the erythrocyte sedimentation rate (ESR) or C reactive protein (CRP), ask you (the patient) to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).&#xD;
These results are then fed into a complex mathematical formula to produce the overall disease activity score. A DAS28 of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.&#xD;
The total scale range is from 2 to 10, with higher scores indicating more disease activity.</description>
        <time_frame>30 Days</time_frame>
        <population>The Osteoarthritis arm was removed; no data was collected for this arm due to low enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
Ticagrelor&#xD;
MTX therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score for 28-joint Counts (DAS28)</title>
          <description>The DAS28 is a composite score derived from 4 of these measures. This '28' version is a simplification of the original DAS score, which requires 44 joints to be counted. Other versions of the DAS28 allow the CRP to be used instead of the ESR, or the omission of either. To calculate the DAS28 your rheumatologist or specialist nurse will:-&#xD;
count the number of swollen joints (out of the 28), count the number of tender joints (out of the 28), take blood to measure the erythrocyte sedimentation rate (ESR) or C reactive protein (CRP), ask you (the patient) to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).&#xD;
These results are then fed into a complex mathematical formula to produce the overall disease activity score. A DAS28 of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.&#xD;
The total scale range is from 2 to 10, with higher scores indicating more disease activity.</description>
          <population>The Osteoarthritis arm was removed; no data was collected for this arm due to low enrollment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Disease Activity</title>
        <description>The VAS is a psychometric response scale that ranges from &quot;no pain&quot; (0) to &quot;worst pain&quot; (100); patients mark a line on a continuum to indicate how they are feeling. Provides global assessment of RA severity.</description>
        <time_frame>30 Days</time_frame>
        <population>The Osteoarthritis arm was removed; no data was collected for this arm due to low enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
Ticagrelor&#xD;
MTX therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Disease Activity</title>
          <description>The VAS is a psychometric response scale that ranges from &quot;no pain&quot; (0) to &quot;worst pain&quot; (100); patients mark a line on a continuum to indicate how they are feeling. Provides global assessment of RA severity.</description>
          <population>The Osteoarthritis arm was removed; no data was collected for this arm due to low enrollment</population>
          <units>Units on VAS scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brachial Artery Diameter</title>
        <description>Endothelial function is characterized by flow-mediated vasodilation of the brachial artery, which is measured by comparing the brachial artery diameter at rest the diameter after increased forearm blood flow (reactive hyperemia). Brachial artery reactivity testing (BART) is a noninvasive technique for evaluating endothelial function</description>
        <time_frame>Baseline, 30 Days</time_frame>
        <population>The Osteoarthritis arm was removed; no data was collected for this arm due to low enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
Ticagrelor&#xD;
MTX therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brachial Artery Diameter</title>
          <description>Endothelial function is characterized by flow-mediated vasodilation of the brachial artery, which is measured by comparing the brachial artery diameter at rest the diameter after increased forearm blood flow (reactive hyperemia). Brachial artery reactivity testing (BART) is a noninvasive technique for evaluating endothelial function</description>
          <population>The Osteoarthritis arm was removed; no data was collected for this arm due to low enrollment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis</title>
          <description>-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks&#xD;
Ticagrelor&#xD;
MTX therapy</description>
        </group>
        <group group_id="E2">
          <title>Osteoarthritis</title>
          <description>-Diagnosis of osteoarthritis made by physician.&#xD;
MTX therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Berger</name_or_title>
      <organization>NYU Langone</organization>
      <phone>212-263-0855</phone>
      <email>Jeffrey.Berger@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

